Open AccessTocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies
Author(s) -
Monica Kaminski,
Subin Sunny,
Khayala Balabayova,
Avneet Kaur,
Aanchal Gupta,
Marie Abdallah,
John Quale
Publication year - 2020
Publication title -
international journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.278
H-Index - 89
eISSN - 1878-3511
pISSN - 1201-9712
DOI - 10.1016/j.ijid.2020.09.1447
Subject(s) - tocilizumab , medicine , cytokine release syndrome , cytokine storm , retrospective cohort study , covid-19 , gastroenterology , surgery , disease , infectious disease (medical specialty)
The release of pro-inflammatory cytokines, resulting in cytokine storm syndrome, contributes to the morbidity and mortality associated with COVID-19 disease. This study aimed to compare the effects of intravenous (IV) and subcutaneous (SC) tocilizumab, an IL-6 receptor antagonist, on respiratory parameters and clinical outcome in patients with COVID 19.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom